Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; magnesium stearate; povidone; sodium dihydrogen citrate; titanium dioxide; hypromellose; peg-40 stearate - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: povidone; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; sodium dihydrogen citrate; titanium dioxide; hypromellose; peg-40 stearate - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: povidone; sodium dihydrogen citrate; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; peg-40 stearate - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - linezolid, quantity: 600 mg - injection, solution - excipient ingredients: citric acid; glucose monohydrate; sodium hydroxide; hydrochloric acid; water for injections; sodium citrate dihydrate - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - linezolid, quantity: 600 mg - injection, solution - excipient ingredients: citric acid; glucose monohydrate; sodium hydroxide; hydrochloric acid; water for injections; sodium citrate dihydrate - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - linezolid, quantity: 600 mg - tablet - excipient ingredients: magnesium stearate; titanium dioxide; silicon dioxide; croscarmellose sodium; hypromellose; diethyl phthalate; microcrystalline cellulose; povidone; purified talc; ethylcellulose - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. it has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - linezolid, quantity: 600 mg - tablet - excipient ingredients: titanium dioxide; ethylcellulose; silicon dioxide; magnesium stearate; croscarmellose sodium; purified talc; diethyl phthalate; hypromellose; povidone; microcrystalline cellulose - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. it has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - linezolid, quantity: 600 mg - tablet - excipient ingredients: croscarmellose sodium; purified talc; ethylcellulose; magnesium stearate; titanium dioxide; silicon dioxide; diethyl phthalate; povidone; microcrystalline cellulose; hypromellose - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. it has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - linezolid, quantity: 600 mg - tablet - excipient ingredients: povidone; hypromellose; magnesium stearate; silicon dioxide; microcrystalline cellulose; ethylcellulose; titanium dioxide; diethyl phthalate; croscarmellose sodium; purified talc - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. it has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - linezolid, quantity: 600 mg - tablet - excipient ingredients: povidone; croscarmellose sodium; purified talc; silicon dioxide; microcrystalline cellulose; diethyl phthalate; magnesium stearate; ethylcellulose; hypromellose; titanium dioxide - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. it has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.